CSIMarket
 
Bristol myers Squibb Company  (BMY)
Other Ticker:  
 
 
Price: $41.2400 $-0.30 -0.722%
Day's High: $41.675 Week Perf: -4.89 %
Day's Low: $ 41.07 30 Day Perf: -7.74 %
Volume (M): 17,426 52 Wk High: $ 66.46
Volume (M$): $ 718,628 52 Wk Avg: $54.55
Open: $41.41 52 Wk Low: $41.07



 Market Capitalization (Millions $) 83,397
 Shares Outstanding (Millions) 2,022
 Employees 32,200
 Revenues (TTM) (Millions $) 45,534
 Net Income (TTM) (Millions $) -6,135
 Cash Flow (TTM) (Millions $) 286
 Capital Exp. (TTM) (Millions $) 1,215

Bristol Myers Squibb Company
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare related products.

The Company has four reportable segments'Pharmaceuticals, Oncology Therapeutics Network (OTN), Nutritionals and Other Healthcare. The Pharmaceuticals segment is made up of the global pharmaceutical and international (excluding Japan) consumer medicines business. The OTN segment provides oncology products, supportive care products and related supplies to office-based oncologists in the United States. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula business. The Other Healthcare segment consists of ConvaTec, Medical Imaging and Consumer Medicines (North America and Japan) businesses.

In the Company's Pharmaceuticals segment and in its ConvaTec and Medical Imaging businesses, the Company promotes its products in medical journals and directly to health care providers such as doctors, nurse practitioners, physician assistants, pharmacists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the United States through direct-to-consumer print, radio and television advertising.

The Company's operations include several pharmaceutical sales organizations. Each sales organization markets a distinct group of products and is typically based on particular therapeutic areas or physician groups. These sales organizations often focus on selling new products when they are introduced, and marketing to physicians is increasingly targeted at specialists and high value primary care physicians.

The Company's prescription pharmaceutical products are sold principally to wholesalers, but the Company also sells directly to retailers, hospitals, clinics, government agencies and pharmacies.'Pharmaceutical wholesalers in the United States are;'McKesson Corporation (McKesson), Cardinal and AmerisourceBergen Corporation.

Competition

The markets in which Bristol-Myers Squibb competes are generally broad-based and highly competitive. The principal means of competition vary among product categories and business groups.

The Company's Pharmaceuticals segment competes with other worldwide research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers. Important competitive factors include product efficacy, safety and ease of use, price and demonstrated cost-effectiveness, marketing effectiveness, product labeling, service and research and development of new products and processes. Sales of the Company's products can be impacted by new studies that indicate a competitor's product has greater efficacy for treating a disease or particular form of disease than one of the Company's products.



   Company Address: Route 206 & Province Line Road Princeton 8543 NJ
   Company Phone Number: 252-4621   Stock Exchange / Ticker: NYSE BMY
   


Customers Net Income fell by BMY's Customers Net Profit Margin fell to

-30.62 %

2.71 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -4.56%    
ABT        0.72% 
JNJ   -2.84%    
LLY        3.1% 
MRK   -1.15%    
PFE        1.23% 
• View Complete Report
   



Business Update

Scenic Biotech Partners with Bristol Myers Squibb to Accelerate Drug Target Development

Published Tue, Apr 30 2024 9:47 AM UTC

In a bid to expedite the development of drug targets, Scenic Biotech, a pioneer in modifier therapies for severe genetic disorders, has announced a research collaboration with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to identify target biology for indication selection and expansion, supporting Bristol Myers Squibb's efforts to advance their drug development ...

Bristol Myers Squibb Company

Bristol Myers Squibb Defies Expectations with Surprising Topline Growth Despite Recent Setbacks

Revolutionizing the field of immunotherapy, Bristol Myers Squibb and Cellares have recently announced a transformative collaboration that aims to expand the production of CAR T cell therapies. This partnership, valued at up to $380 million, involves a worldwide capacity reservation and supply agreement, with the goal of bringing cell therapy to a greater number of patient groups in a shorter timeframe.
Bristol Myers Squibb, a renowned pharmaceutical giant headquartered in Princeton, New Jersey, has joined forces with Cellares, a leading Integrated Development and Manufacturing Organization (IDMO) focused on the clinical and industrial-scale production of cell therapies. The two companies have publicly declared their commitment to this groundbreaking venture.

Business Update

Bristol Myers Squibb and Cellares Enter a $380M Supply Agreement, Bolstering the Manufacture and Access to CAR T Cell Therapies

Published Mon, Apr 22 2024 11:47 AM UTC

Revolutionizing the field of immunotherapy, Bristol Myers Squibb and Cellares recently announced their collaborative venture on a worldwide capacity reservation and supply agreement, a business transaction valued at an upfront payment and milestones of up to $380 million. This partnership seeks to facilitate the expansion of CAR T cell therapies production in a move that pro...

Merger and Acquisition

Bristol Myers Squibb Amplifies Neuroscience Portfolio with Acquisition of Karuna Therapeutics, Spearheading Transformation in Drug Development

Published Mon, Mar 18 2024 12:44 PM UTC

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Expands Neuroscience Portfolio
PRINCETON, N.J. - In a groundbreaking move, Bristol Myers Squibb (NYSE: BMY) announced today the successful completion of its acquisition of Karuna Therapeutics, Inc. This strategic move further solidifies Bristol Myers Squibb's commitment to expanding its neuroscience portf...

Business Update

Bristol Myers Squibb's Tender Offer for RayzeBio Expires Amid Challenges in Supplier Revenues and Cost of Sales

Published Fri, Feb 23 2024 11:59 AM UTC

Bristol Myers Squibb, a leading global biopharmaceutical company, has announced that its tender offer to acquire all outstanding shares of RayzeBio, Inc. has expired. The company's decision comes as it faces challenges in its supplier revenues and an increase in the cost of sales. This article aims to ly analyze the facts surrounding these developments.1. Bristol Myers Squib...






 

Bristol Myers Squibb's Segments
 
Eliquis
 Segment     of total Revenue
SPRYCEL
 Segment     of total Revenue
ABILIFY
 Segment     of total Revenue
Erbitux
 Segment     of total Revenue
SUSTIVA
 Segment     of total Revenue
BARACLUDE
 Segment     of total Revenue
ORENCIA
 Segment     of total Revenue
Other
 Segment     of total Revenue
Total Pharmaceuticals
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bristol Myers Squibb announced annual revenue outlook on

Earnings Outlook
Bristol myers Squibb Company issued annual earnings guidance on

 
Geographic Revenue Dispersion
United States
EMEA
Other




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com